Filtered By:
Drug: Taxotere
Therapy: Radiation Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 34 results found since Jan 2013.
Protective effects of exogenous melatonin therapy against oxidative stress to male reproductive tissue caused by anti-cancer chemical and radiation therapy: a systematic review and meta-analysis of animal studies
ConclusionIn male rodents, melatonin therapy was related to improved testicular histopathology, reproductive hormones, testis and body weights, and reduced levels of oxidative markers in testicular tissues of male rodents. Future meticulous studies are recommended to provide a robust scientific backbone for human applications.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022355293, identifier CRD42022355293.
Source: Frontiers in Endocrinology - August 28, 2023 Category: Endocrinology Source Type: research
Prostate Stereotactic Body Radiation Therapy Margins, Accelerated Partial Breast Irradiation Techniques, Total Neoadjuvant Therapy Local Control, Hyperfractionated Reirradiation, Hyaluronic Acid Rectal Spacer, and Concurrent Docetaxel for Head and Neck Cancer
Pract Radiat Oncol. 2023 Jul-Aug;13(4):267-272. doi: 10.1016/j.prro.2023.04.005.NO ABSTRACTPMID:37391233 | DOI:10.1016/j.prro.2023.04.005
Source: Cancer Control - June 30, 2023 Category: Cancer & Oncology Authors: Laura Dover Caleb Dulaney Source Type: research
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
CONCLUSIONS: After a median follow-up of 10.4 yr among surviving patients, no significant differences are observed in clinical outcomes between the experimental and control arms. These data suggest that docetaxel should not be used for high-risk localized prostate cancer. Additional research may be warranted using novel predictive biomarkers.PATIENT SUMMARY: No significant differences in survival were noted after long-term follow-up for high-risk localized prostate cancer patients in a large prospective trial where patients were treated with androgen deprivation therapy + radiation to the prostate ± docetaxel.PMID:3717924...
Source: Cancer Control - May 13, 2023 Category: Cancer & Oncology Authors: Oliver Sartor Theodore G Karrison Howard M Sandler Leonard G Gomella Mahul Amin James Purdy Jeff M Michalski Mark G Garzotto Nadeem Pervez Alexander G Balogh George B Rodrigues Luis Souhami M Neil Reaume Scott G Williams Raquibul Hannan Christopher U Jone Source Type: research
Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma
CONCLUSIONS: This regimen produced a 10-year overall survival of 68% with a 10-year metastasis-free survival of 58%. Grade >2 toxicity was minimal. These limited data suggest that the addition of concurrent weekly docetaxel to high-dose IMRT for high-risk prostate cancer warrants further investigation.PMID:36420198 | PMC:PMC9677196 | DOI:10.1016/j.adro.2022.100935
Source: Adv Data - November 24, 2022 Category: Epidemiology Authors: Shauna McVorran Thomas Keane David T Marshall Source Type: research
Evolutionary Action Score of < em > TP53 < /em > Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234
CONCLUSIONS: The docetaxel arm was associated with better survival than the cisplatin arm for patients with wild-type or low-risk EAp53. These benefits appear to be largely driven by a reduction in DM.PMID:36420184 | PMC:PMC9677209 | DOI:10.1016/j.adro.2022.100989
Source: Adv Data - November 24, 2022 Category: Epidemiology Authors: Chieko Michikawa Pedro A Torres-Saavedra Natalie L Silver Paul M Harari Merrill S Kies David I Rosenthal Quynh-Thu Le Richard C Jordan Dzifa Y Duose Saradhi Mallampati Sanchit Trivedi Rajyalakshmi Luthra Ignacio I Wistuba Abdullah A Osman Olivier Lichtarg Source Type: research
The 99mTc-MIP-1404 PSMA Uptake in the Isolated Paratracheal Lymph Node From the Prostate Adenocarcinoma
Clin Nucl Med. 2022 Dec 1;47(12):1101-1102. doi: 10.1097/RLU.0000000000004384. Epub 2022 Sep 6.ABSTRACTThe oncologist consulted a 56-year-old man after receiving prostate-specific antigen screening results. Prostate-specific antigen level during the screen time was 33 ng/mL. As a result, poorly differentiated prostate adenocarcinoma with a Gleason score of 9 (5 + 4) was diagnosed. SPECT/CT scan with 99mTc-MIP-1404 PSMA tracer was performed. The 99mTc-PSMA-positive lesions were detected in the prostate, external iliac, obturator lymph nodes of the pelvis, para-aortic, and the right lower paratracheal space. The patient was ...
Source: Clinical Prostate Cancer - November 7, 2022 Category: Cancer & Oncology Authors: Justinas Jonusas Sigitas Tiskevicius Ernestas Janulionis Source Type: research
The current role of local treatment in metastatic prostate cancer: systematic review and meta-analysis
CONCLUSION: Recent data have shown that local treatment combined with systematic therapy, might improve the overall, cancer-specific, and failure-free survivals of patients diagnosed with metastatic prostate cancer. Furthermore, local treatment is both feasible and safe. Further studies evaluating the quality of life of these patients are needed.PMID:36258673 | DOI:10.1080/0284186X.2022.2132113
Source: Acta Oncologica - October 19, 2022 Category: Cancer & Oncology Authors: Willy Baccaglini Antonio F Rodrigues Saulo B Teles Nicolle M Christofe Felipe P A Glina Gustavo C Lemos Rafael Sanchez-Salas Rub én Olivares Arie Carneiro Source Type: research
Efficacy of thymosin α1 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043)
CONCLUSIONS: Administration of thymosin α1 during and after CCRT was associated with significant reductions in G≥2 RP and G3-4 lymphopenia in patients with LANSCLC compared to historic controls.PMID:35870709 | DOI:10.1016/j.ijrobp.2022.07.009
Source: Health Physics - July 23, 2022 Category: Physics Authors: Fangjie Liu Bo Qiu Yu Xi Yifeng Luo Qiaoting Luo Yingjia Wu Naibin Chen Rui Zhou Jinyu Guo Qingping Wu Mai Xiong Hui Liu Source Type: research
The Number of Radiographically Positive Lymph Nodes Further Stratifies Patient Survival Among Clinical N1 Patients With Human Papillomavirus-Associated Oropharyngeal Cancer
CONCLUSIONS: The number of radiographically positive lymph nodes is predictive of PFS and overall survival and could be used to meaningfully subcategorize cN1 patients with HPV(+)OPSCC. We recommend further validation of our proposal that cN1 patients with 1 to 2 radiologically positive lymph nodes be categorized as cN1a, patients with 3 to 4 radiologically positive lymph nodes categorized as cN1b, and patients with >4 radiographically positive lymph nodes categorized as cN1c.PMID:35814859 | PMC:PMC9260100 | DOI:10.1016/j.adro.2022.100926
Source: Adv Data - July 11, 2022 Category: Epidemiology Authors: Roman O Kowalchuk Kathryn M Van Abel Adam B Sauer Linda X Yin Joaquin J Garcia William S Harmsen Eric J Moore Daniel L Price Ashish V Chintakuntlawar Katharine R Price Scott C Lester Michelle Neben Wittich Samir H Patel Robert L Foote Daniel M Ma Alex A N Source Type: research
Hypofractionated Radiotherapy Combined with Weekly Chemotherapy in Patients with Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-arm Phase II Study (GASTO-1042)
CONCLUSIONS: IMRT-HRT and concurrent weekly docetaxel/nedaplatin was effective and well-tolerated in unresectable or recurrent TETs. Considering the common out-of-field recurrence, this combined regimen could be an option for repeated radiotherapy. Thymosin α1 might help lower the incidence of pneumonitis and maintain the QOL.PMID:35598797 | DOI:10.1016/j.ijrobp.2022.05.015
Source: Health Physics - May 22, 2022 Category: Physics Authors: Chu Chu Ying Liang Xiaosheng Lin Yimei Liu Songran Liu Jinyu Guo Daquan Wang Junye Wang Hui Liu Bo Qiu Source Type: research
Sintilimab for the treatment of non-small cell lung cancer
This study provides an overview of sintilimab-based clinical trials on NSCLC, and may support further investigation of sintilimab in future clinical trials.PMID:35436956 | DOI:10.1186/s40364-022-00363-7
Source: Cell Research - April 19, 2022 Category: Cytology Authors: Lin Zhang Weihao Lin Fengwei Tan Ning Li Qi Xue Shugeng Gao Yibo Gao Jie He Source Type: research
